<?xml version="1.0" ?>
<tei>
	<teiHeader>
		<fileDesc xml:id="55006316"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
<lb/>
	<email>safcglobal.com<lb/></email>

	<note type="other">Technical Bulletin<lb/></note>

	<docTitle>
	<titlePart>Filtration Trials with SAFC<lb/> ®<lb/> EX-CELL<lb/> ®<lb/> CD Hydrolysate Fusion<lb/></titlePart>
	</docTitle>

	<byline>
	<docAuthor>Mandar Dixit<lb/> 1<lb/> , Zachary Deeds<lb/> 2<lb/> , Geneane Walsh<lb/> 1 and Christopher Sullivan<lb/> 1<lb/> ,<lb/> </docAuthor>
	</byline>

	<byline>
	<affiliation>1<lb/> Sartorius Stedim North America Inc.,</affiliation>
	</byline>

	<address>5 Orville Dr., Bohemia, NY 11716, USA<lb/></address>

	<byline>
	<affiliation>2<lb/> SAFC,</affiliation>
	</byline>

	<address>2909 Laclede Avenue, Saint Louis, MO 63103, USA<lb/></address>

	<div type="abstract">Abstract<lb/> SAFC has recently launched EX-CELL CD Hydrolysate<lb/> Fusion, the first fully chemically defined media<lb/> supplement of its kind in the industry. Sartorius<lb/> Stedim Biotech and SAFC have recently announced<lb/> a wide-ranging joint cooperation agreement to serve<lb/> their customers. As a consequence of this effort, a<lb/> range of 0.2 μm and 0.1 μm sterilizing grade filters<lb/> from different membrane materials were tested for<lb/> throughput and biological activity post-filtration.<lb/></div>

		</front>
	</text>
</tei>
